Multiple myeloma patients are deficient in normal polyclonal serum immunoglobulins. To 26% showed a lack of correlation between the numbers of sIgM+ B cells and serum IgM concentration. We suggest that in patients with multiple myeloma, and in some with MGUS, there exists a mechanism(s) extrinsic to the B cell that mediates an arrest in terminal B lymphocyte maturation.
Introduction
A frequent finding in multiple myeloma is a decrease in normal serum Ig levels that correlates with disease severity (1) . The underlying mechanism is sufficiently powerful to suppress even monoclonal gammopathies unrelated to the myeloma (2, 3) . Although most multiple myeloma patients have greatly reduced numbers of B lymphocytes (4) (5) (6) (7) , it is not clear whether the decreased serum polyclonal Ig is due to lack of B compared the number of surface IgM' (sIgM+)' B cells in peripheral blood, the frequency with which B cells from myeloma patients are transformed by Epstein-Barr virus (EBV) to produce IgM-secreting clones in vitro (10-13), and serum IgM levels. We find that a substantial subset of myeloma patients and some individuals with monoclonal gammopathy of undetermined significance (MGUS) Peripheral blood lymphocytes (PBL) were purified by centrifugation over Ficoll-paque (Pharmacia Fine Chemicals, Piscataway, NJ), and the composition of the resulting cell population was determined by a differential count using Giemsa stain. Aliquots were characterized for number of sIg' and sIgM' B cells by indirect immunofluorescence (IF) (4) . A second aliquot of cells was subjected to separation by rosetting with 2-amino-ethylisothiouronium bromide hydrobromidetreated sheep erythrocytes to obtain an E-population for use in EBV transformation procedures (10). Briefly, purified PBL (5 X 105_106) were aliquoted into v-bottom microtiter wells, and were resuspended in 50 Al of the test murine anti-human antibody and incubated for 60 min at 4°C. After washing, the cell pellet was resuspended in 50 MlI of a 1/20 dilution of F(ab')2 fragments of sheep anti-mouse Ig labeled with fluorescein isothiocyanate (FITC) (Tago Inc., Burlingame, CA), incubated for 60 min at 4°C, and washed twice. Cells were then resuspended in warm saline and incubated for 10 min at 370C to allow cap formation (4) followed by fixation of cells in 1% formalin. The patients analyzed for this study include the set of patients analyzed previously (4) where B cells were defined by their expression of HLA -DR, and of 41H * 16, a marker for mature B cells (14) . The number of B cells defined by these two markers was within the same range as those defined by their ability to bind anti-IgM.
Plasma IgM levels were determined by nephlometry (Behring Diagnostics, American Hoechst Corp., San Diego, CA). Plasma samples were taken from the same tubes of blood used for purification of PBL.
EBV-transformation. The techniques of Winger et al. (10) were used to infect the E-cells with EBV followed by their distribution into microtiter wells (Flow Laboratories, Inc., McLean, VA), containing 10' E-irradiated feeder cells (1,500 rads) from normal fresh buffy coat. EBV-infected cells were plated at 3 X 103 to one cell per well in a decreasing threefold dilution series in RPMI (Gibco Canada, Burlington, Ontario) plus 20% fetal calf serum (Flow Laboratories, Inc.). Supernatants were collected at 3 wk and tested for IgM activity as described below. The frequency of transformed cells within an EBVinfected E-population was defined as the reciprocal of the cell number at which 37% of the microculture wells in the limiting dilution series were negative; on average each well receives one transformed B cell at this cell concentration (1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] (36, 37) and in murine model systems (38) , its reversal might lead to a better prognosis for myeloma patients. Experiments are in progress to determine the mechanism(s) mediating B lineage differentiation arrest in myeloma, with particular emphasis on a search for suppressor T cells.
